Today, Thera4Care celebrates a significant milestone, highlighting the dedication, hard work, and strong commitment of its partners during the project's initial months. We have released the first Thera4Care public survey, focusing on Theranostic Radiopharmaceuticals in Europe.
This survey is specifically designed for professionals and aims to provide a comprehensive overview of the current state of Theranostic Radiopharmaceuticals across Europe.
As Thera4Care strives to revolutionise precision oncology and position Europe as a global leader in theranostics within the next five years, understanding the current landscape is crucial. The insights gathered will help identify key challenges in regulation, production, research, and clinics that need to be addressed.
We warmly invite professionals from diverse backgrounds to participate in the survey and contribute to shaping the future of patient treatment.
The survey can be accessed in the following link: https://forms.gle/SiYJy1Ko6w6mgXQT6